A Secret Weapon For M3541
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate multiple intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Primary trial objectives were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis o